Humira has enjoyed high-priced U.S. exclusivity for 20 years. Its challengers could save the health care system $9 billion and herald savings from the whole class of drugs called biosimilars.
Subscribe to continue reading this article.
Already subscribed? To log in, click here.
Originally Published:
